PPARA and plasma cell myeloma: Our findings provide a new avenue to investigate the effects of PPAR agonists that are commonly used for the treatment of diabetes and dyslipidemia on IMiD activity and to develop novel agents targeting the PPAR pathway for enhanced anti-myeloma activity.